|
13 Aug 2020 |
Debiopharm's IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients
|
|
13 Aug 2020 |
Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies
|
|
13 Aug 2020 |
Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC): IND.239
|
|
12 Aug 2020 |
Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506
|
|
12 Aug 2020 |
Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy
|
|
11 Aug 2020 |
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
|
|
11 Aug 2020 |
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space
|
|
10 Aug 2020 |
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
|
|
08 Aug 2020 |
FDA Approves New Opioid for Intravenous Use in Hospitals, Other Controlled Clinical Settings
|
|
08 Aug 2020 |
FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older
|
|
07 Aug 2020 |
U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children
|
|
07 Aug 2020 |
ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1
|
|
06 Aug 2020 |
Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients
|
|
06 Aug 2020 |
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
|
|
06 Aug 2020 |
MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation
|
|
06 Aug 2020 |
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
|
|
04 Aug 2020 |
HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology
|
|
04 Aug 2020 |
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
|
|
04 Aug 2020 |
Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers
|
|
04 Aug 2020 |
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis
|
|
03 Aug 2020 |
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
|
|
03 Aug 2020 |
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital
|
|
03 Aug 2020 |
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
|
|
03 Aug 2020 |
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
|
|
03 Aug 2020 |
Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma
|
